Recent Developments

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 15, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM syndrome

Cambridge, MA – May 17, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-RD, the company’s CXCR4 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P001-IO and Inlyta®(axitinib) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 16, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-IO, the company’s CXCR4 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 15, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

ContraFect Announces First Quarter 2018 Financial Results

YONKERS, N.Y. , May 10, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the first quarter ended … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome

NEW YORK, N.Y. and CAMBRIDGE, Mass. April 24, 2018 – The Jeffrey Modell Foundation, a nonprofit organization for primary immunodeficiency diseases, and X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs, today announced that they are jointly … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

BOSTON, Mass., April 19, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity

CAMBRIDGE, Mass., April 16, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today highlighted data from a presentation at the 2018 American Association … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of data on its lead … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Cerecor Appoints Simon Pedder to its Board of Directors

BALTIMORE, MD — (Marketwired) — 04/09/18 — Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. “We are delighted to welcome Dr. Pedder to our Board.” said Dr. Uli Hacksell, … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

Strategic acquisitions transform Cerecor into a leading U.S. Pediatric Pharmaceutical Company Company announces initiation of a clinical development program for CERC-301 in Neurogenic Orthostatic Hypotension BALTIMORE, MD — (Marketwired) — 04/02/18 — Cerecor Inc. (NASDAQ: CERC) today announced financial results … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Cerecor Appoints Peter Greenleaf as Chief Executive Officer

BALTIMORE, MD — (Marketwired) — 03/28/18 — Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company’s board since May 2017. He brings to … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off